Anzeige
Mehr »
Freitag, 20.06.2025 - Börsentäglich über 12.000 News
+435 % Beteiligungsrendite durch TAO nach £5 Mio. Finanzierung und Bitcoin-Treasury-Strategie!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C86J | ISIN: US7168174081 | Ticker-Symbol:
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PETVIVO HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
PETVIVO HOLDINGS INC 5-Tage-Chart
ACCESS Newswire
346 Leser
Artikel bewerten:
(1)

New to The Street and Sight & Sound's Visionaries Series Premieres Tonight on Bloomberg, Featuring PetVivo and Its Revolutionary SPRYNG OsteoCushion Technology

New to The Street and Sight & Sound are thrilled to announce the premiere of their latest episode in the Visionaries series, airing tonight at 9:30 PM PST on Bloomberg as sponsored programming.

NEW YORK, NY / ACCESSWIRE / September 5, 2024 / New to The Street and Sight & Sound are thrilled to announce the premiere of their latest episode in the Visionaries series, airing tonight at 9:30 PM PST on Bloomberg as sponsored programming. This highly anticipated episode will spotlight PetVivo Holdings, Inc. (OTCQB:PETV,PETVW) and its revolutionary SPRYNG product, a ground-breaking solution that is transforming joint health treatment for animals. SPRYNG, PetVivo's proprietary injectable veterinary medical device, has garnered widespread attention for its effectiveness in the management of osteoarthritis and other musculoskeletal conditions in animals. By mimicking and reinforcing natural joint cartilage, SPRYNG offers a breakthrough, drug-free option for veterinarians seeking long-term solutions to improve the quality of life for pets.

Nasdaq Billboard NTTS

Nasdaq Billboard NTTS
NASDAQ

Sneak peek here https://youtu.be/-6jmRoEBRVs?si=hlECEUkRBPorAfMn

Currently, SPRYNG has been used in over 800 veterinary clinics across all 50 U.S. states, making it a leading product in veterinary care. This episode of Visionaries takes viewers inside PetVivo's Minnesota lab and offices, where John Lai, CEO of PetVivo, along with leading scientists and veterinary experts, will provide an in-depth exploration of the science behind SPRYNG and its transformative impact on animal health.

"We are excited to showcase PetVivo in this new episode of Visionaries, which perfectly aligns with our mission to highlight innovative companies making a difference in their industries," said John Lai, CEO of PetVivo. "SPRYNG has the potential to redefine how veterinarians approach joint health, and we are thrilled to bring this story to a national audience."

After airing on Bloomberg, this episode will be distributed across New to The Street's vast digital platforms, including its 1.4 million subscriber YouTube channel and 300,000+ social media followers on Twitter, LinkedIn, and Instagram. The extended reach ensures that the segment will
continue to engage a broad audience well beyond its initial television broadcast.

About PetVivo Holdings, Inc.

PetVivo Holdings, Inc. (OTCQB:PETV, PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.

PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company's commercially launched flagship product, Spryng with OsteoCushion

Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses. For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email info1@petvivo.com or visit petvivo.com or sprynghealth.com.

About New to The Street

New to The Street is a long-running sponsored television program that highlights emerging companies and forward-thinking brands. With nearly two decades of experience, New to The Street has produced over 800 shows, airing on major U.S. networks including FOX Business and Bloomberg. After airing on television, the content is shared on New to The Street's 1.4 million subscriber YouTube channel and across its 300,000+ social media followers on Twitter, LinkedIn, and Instagram, providing continuous exposure for the featured companies.

For media inquiries, please contact:

Contact Information

Monica Brennan
Head of Operations
monica@newtothestreet.com
6316828499

SOURCE: New to The Street



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.